All In Biotech

Drug Trial Radar · NCT01243177

Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older

A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.

Last checked: Nov 20, 2026Latest source record: Feb 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 888 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

888

Actual

Start

Apr 2011

Primary completion

Jul 2015

Study completion Aug 2015

Sponsor

Lead sponsor
UCB BIOSCIENCES GmbHUCB
Sponsor type
Industry
Collaborators
Eden Sarl
First posted
Nov 18, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Compare efficacy and safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR) as monotherapy in newly or recently newly diagnosed subjects with a primary efficacy endpoint of 6-month seizure freedom. Noninferiority design to show a similar risk/benefit balance between Lacosamide (LCM) and Carbamazepine-CR (CBZ-CR).

Conditions

  • Epilepsy
  • Monotherapy

Interventions

  • LacosamideDrug

    Lacosamide: * Strengths: 50 mg / 100 mg * Form: tablets * Dosage: total daily target dose of 200 mg, 400 mg or 600 mg. 1 dose reduction was allowed from either 600 mg to 500 mg or from 400 mg to 300 mg total daily dose * Duration: up to 118 weeks

  • Carbamazepine-Controlled ReleaseDrug

    Carbamazepine-CR: * Strengths: 200 mg * Form: tablets * Dosage: total daily target dose of 400 mg, 800 mg or 1200 mg. 1 dose reduction was allowed from either 1200 mg to 1000 mg or from 800 mg to 600 mg total daily dose * Duration: up to 118 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects in the Full Analysis Set (FAS) Remaining Seizure Free for 6 Consecutive Months (26 Consecutive Weeks) of Treatment Following Stabilization at the Last Evaluated Dose for Each SubjectTime frame: 6 consecutive months (26 consecutive weeks) of treatment following stabilization at the last evaluated dose for each subject
  2. Proportion of Subjects in the Per Protocol Set (PPS) Remaining Seizure Free for 6 Consecutive Months (26 Consecutive Weeks) of Treatment Following Stabilization at the Last Evaluated Dose for Each SubjectTime frame: 6 consecutive months (26 consecutive weeks) of treatment
  3. Number of Subjects With at Least One Treatment-emergent Adverse Event (AE) During the Treatment Phase (up to 113 Weeks)Time frame: Duration of the Treatment Phase (up to 113 weeks)
  4. Number of Subjects Who Withdraw From the Study Due to a Treatment-emergent Adverse Event (AE) During the Treatment Phase (up to 113 Weeks)Time frame: Duration of the Treatment Phase (up to 113 weeks)
  5. Number of Subjects With at Least One Treatment-emergent Serious Adverse Event (SAE) During the Treatment Phase (up to 113 Weeks)Time frame: Duration of the Treatment Phase (up to 113 weeks)

Locations

184 sites in 29 countries. Site status is shown where the registry gives one.

  • 786

    Alabaster, Alabama

  • 799

    Huntsville, Alabama

  • 780

    Phoenix, Arizona

  • 777

    Little Rock, Arkansas

  • 795

    Ocala, Florida

  • 789

    Panama City, Florida

  • 776

    Port Charlotte, Florida

  • 779

    Manhattan, Kansas

  • 874

    Charlotte, North Carolina

  • 876

    Hickory, North Carolina

  • 873

    Raleigh, North Carolina

  • 794

    Oklahoma City, Oklahoma

  • 881

    Mansfield, Texas

  • 790

    Madison, Wisconsin

  • 798

    Casper, Wyoming

  • 104

    Chatswood, Australia

  • 105

    Clayton, Australia

  • 106

    East Gosford, New South Wales, Australia

  • 109

    Randwick, New South Wales, Australia

  • 102

    Westmead, New South Wales, Australia

  • 103

    Herston, Queensland, Australia

  • 100

    Woodville, South Australia, Australia

  • 101

    Fitzroy, Victoria, Australia

  • 108

    Heidelberg, Victoria, Australia

  • 127

    Bruges, Belgium

  • 134

    Bruges, Belgium

  • 128

    Hasselt, Belgium

  • 126

    Leuven, Belgium

  • 805

    Blagoevgrad, Bulgaria

  • 807

    Panagyurishte, Bulgaria

  • 803

    Pleven, Bulgaria

  • 810

    Rousse, Bulgaria

  • 806

    Sofia, Bulgaria

  • 808

    Sofia, Bulgaria

  • 811

    Sofia, Bulgaria

  • 809

    Veliko Tarnovo, Bulgaria

  • 155

    Calgary, Canada

  • 158

    Halifax Nova Scotia, Canada

  • 156

    Hamilton, Canada

  • 159

    Veilleux, Canada

Showing 40 of 184 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.